
MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer ...
MAIA Biotechnology, Inc. MAIA on Thursday revealed updated data from its THIO-101 pivotal Phase 2 clinical trial. The trial is evaluating its lead clinical candidate, ateganosine (THIO), sequenced with Regeneron Pharmaceutical Inc’s REGN immune checkpoint …